Patent, Extension and Data Exclusively Expiry Snapshots by Ark Patent Intelligence Now Available at MarketPublishers.com

Market Publishers Ltd announces that in-demand Ark Patent Intelligence reports on key patent issues of different drugs have been added to its catalogue.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
TD The Market Publishers Ltd

http://marketpublishers.com/

London, UK (PRWEB) June 10, 2014

Market Publishers Ltd announces that in-demand Ark Patent Intelligence reports on key patent issues of different drugs have been added to its catalogue.

Losartan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries). The report is an essential source of accurate data on Losartan, including vital details on key patents, extensions and data exclusive expiry for 9 countries (50 country coverage also at hand). The study sheds light on the main regulative issues, reviews the performance of the key players, contains the expert constraint analysis, provides a full consideration of orphan, paediatric and complex data, examines patents interpreted and assigned to categories. The topical report includes a summary of Losartan’s dosage forms, indications, strengths and active ingredient forms; offers examples of crucial patent documents…

Silodosin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries). The topical study is the most extensive source of patent data available. It is a trustworthy database frequently updated and covering the major related aspects. Moreover, the report covers the key patents, presents an all-round review of orphan, paediatric and complex data exclusively, highlights patents assigned and interpreted t categories, and also offers reliable, verifiable and complete data on Silodosin patent, extension and data exclusivity expiry for 9 countries (50 country coverage is also provided)…

Irbesartan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries). The report is a unique source of verified and trustworthy data on Irbesartan usage and main patents. It provides vital patent documentation, reviews the key companies, presents detailed discussion of the patent related issues, covers the related regulative policies, contains expert constraint analysis. The report provides a full consideration of paediatric, orphan and complex data exclusivity; gives access to a comprehensive summary of Irbesartan’s indications, dosage forms, strengths and active ingredients…

Raltegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries). The in-demand report provides access to a set of unique authoritative data covering the key patent issues of Raltegravir. It focuses on the 9 major countries (namely Canada, the UK, the US, Italy, Australia, France, Spain, Japan and Germany), but 50 country coverage is also provided. Besides, the study throws light on the major regulative policies, uncovers details on the top companies, offer access to online copies of the patent documents, and also offers a detailed expert constraint analysis…

More in-demand research reports by the publisher can be found at Ark Patent Intelligence page.